This is NOT another name for Selegiline-- I found the article below with a
GOOGLE search--there were many others also.
CLINICAL TRIAL OF RASAGILINE MESYLATE IN EARLY PARKINSON'S DISEASE
Thank you for your interest in Parkinson's research at the Fairview
University Medical Center. We are recruiting individuals with early,
untreated
Parkinson's disease for a study of a new medication called Rasagiline. This
research is being conducted by the Parkinson Study Group under the
sponsorship of Teva Pharmaceuticals. Dr. Paul Tuite of the Department of
Neurology is the local investigator.
Rasagiline is a MAO type B inhibitor and is similar to the drug selegiline
(EldeprylŪ). The purpose of this study is to see if rasagiline improves the
signs and
symptoms of Parkinson's, and to examine how well subjects tolerate the
drug. It may also have a neuroprotective benefit; that is, it may help slow
the
progression of Parkinson's disease.
To qualify for the Rasagiline trial you need to meet the following criteria:
Diagnosis of Parkinson's disease
Male or female age 35 to 80 (upper age limit is flexible)
Good general health and independent in daily activities
Not yet taking or requiring medications for Parkinson's disease
(potential subjects may currently be taking low doses of
anti-parkinsonian medications, but could tolerate stopping such medications
without
significant impact on their overall function)
No significant memory or thinking problems, major depression or
psychiatric illness, or history of drug abuse
No prior history of serious adverse reaction to selegiline (EldeprylŪ)
Potential candidates will be seen for an initial 2- 3 hour screening visit
to determine eligibility for the study. If you are eligible and agree to
participate, you
will be enrolled in the 12 month trial. During the first 6 months of the
study, you will be randomly assigned to one of three groups: placebo
(inactive pill),
low dose or high dose of Rasagiline. During the second phase of the study,
you will receive Rasagiline. Visits to the University will be required
every 4-6
weeks throughout the study. If you require further treatment for
Parkinson's symptoms at any time during the study, you will be started on
additional
standard drug treatment, such as Sinemet.
If you have questions or would like further information, please call the
study coordinator, Brenda Ebbitt, RN,CS at (612) 625-9433.
Camilla Flintermann, CG for Peter 82/70/55
Oxford, Ohio
<[log in to unmask]>
on the web at http://www.geocities.com/camillahf/index.html
and also at http://members.tripod.lycos.nl/genugten/flinterm.htm
"Ask me about the CARE list for Caregivers of Parkinsonians ! "
And visit the CARE webring at http://www.pdcaregiver.org
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
